# Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study

> **NCT06728865** · PHASE2 · RECRUITING · sponsor: **Li-kun Chen** · enrollment: 70 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)
- EGFR Mutation-Positive Lung Cancer
- Brain Metastases
- Leptomeningeal Metastases
- Intracranial Tumor Progression

## Interventions

- **DRUG:** The treatment regimen is Furmonertinib combined with Bevacizumab.

## Key facts

- **NCT ID:** NCT06728865
- **Lead sponsor:** Li-kun Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-04
- **Primary completion:** 2028-02-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2024-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06728865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06728865, "Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06728865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*